Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34657158)

  • 1. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment.
    Song M; Zhu L; Zhang L; Ge X; Cao J; Teng Y; Tian R
    Mol Pharm; 2024 May; 21(5):2340-2350. PubMed ID: 38546166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma.
    Jeising S; Geerling G; Guthoff R; Hänggi D; Sabel M; Rapp M; Nickel AC
    Photodiagnosis Photodyn Ther; 2022 Dec; 40():103049. PubMed ID: 35932958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
    Wei C; Li X
    Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin-loaded microparticles for radiosensitization of preclinical lung and breast metastatic spine cancer.
    Akinduro OO; Suarez-Meade P; Roberts M; Tzeng SY; Sarabia-Estrada R; Schiapparelli P; Norton ES; Gokaslan ZL; Anastasiadis PZ; Guerrero-Cázares H; Green JJ; Quiñones-Hinojosa A
    J Neurosurg Spine; 2023 Apr; 38(4):481-493. PubMed ID: 36585863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
    Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
    Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
    Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
    Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
    Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin inhibits growth of human glioma in vitro without light activation.
    Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    Wei C; Li X
    BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.
    Li Y; Yang S; Yang S
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Photoinduced Biological Properties of Verteporfin.
    Gibault F; Corvaisier M; Bailly F; Huet G; Melnyk P; Cotelle P
    Curr Med Chem; 2016; 23(11):1171-84. PubMed ID: 26980565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockage of glioma cell survival by truncated TEAD-binding domain of YAP.
    Zhao W; Dong QF; Li LW; Yan ZF; Huo JL; Chen XY; Yang X; Li PQ; Fei Z; Zhen HN
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1713-1723. PubMed ID: 33651140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feedforward loop between IMP1 and YAP/TAZ promotes tumorigenesis and malignant progression in glioblastoma.
    Yang J; Wu X; Wang J; Guo X; Chen J; Yang X; Zhong J; Li X; Deng Z
    Cancer Sci; 2023 May; 114(5):2053-2062. PubMed ID: 36308276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
    Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
    ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.